← Back to Screener
Compass Therapeutics, Inc. Common Stock (CMPX)
Price$5.42
Favorite Metrics
Price vs S&P 500 (26W)32.76%
Price vs S&P 500 (4W)7.01%
Market Capitalization$1.08B
All Metrics
Book Value / Share (Quarterly)$1.10
P/TBV (Annual)1.21x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.28
Price vs S&P 500 (YTD)7.59%
EPS (TTM)$-0.31
10-Day Avg Trading Volume3.37M
EPS Excl Extra (TTM)$-0.31
EPS (Annual)$-0.42
ROI (Annual)-33.79%
Cash / Share (Quarterly)$1.17
ROA (Last FY)-30.28%
EBITD / Share (TTM)$-0.33
ROE (5Y Avg)-36.42%
Cash Flow / Share (Annual)$-0.28
P/B Ratio5.49x
P/B Ratio (Quarterly)4.85x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-240.71x
ROA (TTM)-26.35%
EPS Incl Extra (Annual)$-0.42
Current Ratio (Annual)15.02x
Quick Ratio (Quarterly)14.96x
3-Month Avg Trading Volume2.30M
52-Week Price Return252.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.26
P/S Ratio (Annual)1271.21x
Asset Turnover (Annual)0.01x
52-Week High$6.88
EPS Excl Extra (Annual)$-0.42
CapEx CAGR (5Y)-25.65%
26-Week Price Return41.51%
Quick Ratio (Annual)14.96x
13-Week Price Return-0.66%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.02x
Enterprise Value$1,049.885
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-5808.82%
Cash / Share (Annual)$1.17
3-Month Return Std Dev58.81%
Net Income / Employee (TTM)$-1
ROE (Last FY)-33.79%
Net Interest Coverage (Annual)-233.80x
EPS Basic Excl Extra (Annual)$-0.42
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.31
ROI (TTM)-29.94%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.44
Price vs S&P 500 (52W)217.85%
Year-to-Date Return11.73%
5-Day Price Return15.38%
EPS Normalized (Annual)$-0.42
ROA (5Y Avg)-33.12%
Net Profit Margin (Annual)-5808.82%
Month-to-Date Return13.42%
Cash Flow / Share (TTM)$-0.32
EBITD / Share (Annual)$-0.45
Operating Margin (Annual)-6661.76%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-36.42%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.31
P/TBV (Quarterly)1.37x
P/B Ratio (Annual)4.85x
Book Value / Share (Annual)$1.10
Price vs S&P 500 (13W)-3.53%
Beta1.32x
Revenue / Share (TTM)$0.00
ROE (TTM)-29.94%
52-Week Low$1.60
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.35
4.38
4.38
4.36
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CMPXCompass Therapeutics, Inc. Common Stock | — | — | — | — | $5.42 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Compass Therapeutics is a clinical-stage oncology biopharmaceutical company developing antibody-based immunotherapies to treat cancer. The company uses proprietary antibody discovery platforms and bispecific engineering capabilities to design targeted therapeutic combinations with favorable manufacturing profiles. Its pipeline includes multiple candidates such as CTX-009, CTX-471, CTX-8371, and a VEGF-A bispecific, leveraging its StitchMabs and common light chain technologies to advance treatment options.